Theratechnologies Announces New Head of Investor Relations
31 Mai 2022 - 1:32PM
Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX:
TH) (NASDAQ: THTX), a biopharmaceutical company focused on the
development and commercialization of innovative therapies, today
announced that Elif McDonald has joined the team as Senior
Director, Investor Relations.
"We are pleased to welcome Elif to lead our
dedicated in-house investor relations efforts,” said Paul Lévesque,
President and Chief Executive Officer, Theratechnologies. “Her
comprehensive investor relations experience and robust network
across the healthcare and financial communities will be a great
asset as we advance awareness of our strong commercial portfolio,
extensive research pipeline and vision for the future within
capital markets. We look forward to enhancing our engagement with
the investment community as we continue to strive for breakthrough
therapies in human health while seeking further growth
opportunities.”
“I am excited to join a world-class team of
professionals with a collaborative culture committed to improving
patient outcomes," said Ms. McDonald. "Theratechnologies has
developed a dynamic pipeline, brought life enhancing drugs to
market, built a revenue generating commercial business, all while
delivering a unique investment proposition. I look forward to
elevating the Company’s visibility across capital markets and
effectively communicating the corporate business strategy.”
Ms. McDonald brings a wealth of experience
earned over 20 years in capital markets, investor relations,
financial communications, and corporate governance. She has
extensive experience managing investor relations platforms for
companies of diverse market capitalizations and sectors, with a
focus on Biotech and Pharmaceutical firms listed on the NYSE,
NASDAQ and TSX. She has worked with leading financial institutions,
as well as with renowned communications and governance experts in
Canada and the United States. She is a graduate of the University
of Ottawa with a bachelor’s degree in Economics.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking
statements and forward-looking information, or, collectively,
forward-looking statements, within the meaning of applicable
securities laws, that are based on our management’s beliefs and
assumptions and on information currently available to our
management. You can identify forward-looking statements by terms
such as "may", "will", "should", "could", “promising”, “would”,
"outlook", "believe", "plan", "envisage", "anticipate", "expect"
and "estimate", or the negatives of these terms, or variations of
them. The forward-looking statements contained in this press
release include, but are not limited to, statements regarding our
commercial portfolio, research pipeline and the development of new
medicines. Although the forward-looking information contained in
this press release is based upon what the Company believes are
reasonable assumptions in light of the information currently
available, investors are cautioned against placing undue reliance
on this information since actual results may vary from the
forward-looking information. Certain assumptions made in preparing
the forward-looking statements include that: sales of EGRIFTA SV®
and Trogarzo® in the United States will increase over time; the
Company’s commercial practices in the United States will not be
found to be in violation of applicable laws; the long-term use of
EGRIFTA SV® and Trogarzo® will not change their respective current
safety profile; no recall or market withdrawal of EGRIFTA SV® and
Trogarzo® will occur; no laws, regulation, order, decree or
judgment will be passed or issued by a governmental body negatively
affecting the marketing, promotion or sale of EGRIFTA SV® and
Trogarzo®; continuous supply of EGRIFTA SV® and Trogarzo® will be
available; the Company’s relations with third-party suppliers of
EGRIFTA SV® and Trogarzo® will be conflict-free and such
third-party suppliers will have the capacity to manufacture and
supply EGRIFTA SV® and Trogarzo® to meet market demand on a timely
basis; no biosimilar version of EGRIFTA SV® will be approved by the
FDA; the Company’s intellectual property will prevent companies
from commercializing biosimilar versions of EGRIFTA SV® in the
United States; results obtained in preclinical studies with respect
to our oncology development program will be replicated into humans;
and, the Company’s business plan will not be substantially
modified; and our research programs will lead to the discovery of
new drugs. Forward-looking information assumptions are subject to a
number of risks and uncertainties, many of which are beyond
Theratechnologies’ control that could cause actual results to
differ materially from those that are disclosed in or implied by
such forward-looking information. These risks and uncertainties
include, but are not limited to, those related to or arising from:
the Company’s ability and capacity to grow the sales of EGRIFTA SV®
and Trogarzo® successfully in the United States; the Company’s
capacity to meet supply and demand for its products; the market
acceptance of EGRIFTA SV® and Trogarzo® in the United States; the
continuation of the Company’s collaborations and other significant
agreements with its existing commercial partners and third-party
suppliers and its ability to establish and maintain additional
collaboration agreements; the success and pricing of other
competing drugs or therapies that are or may become available in
the marketplace; the Company’s ability to protect and maintain its
intellectual property rights in EGRIFTA SV® and tesamorelin; the
Company’s ability to successfully conduct its Phase 1 clinical
trial using TH1902 in various types of cancer; the discovery of a
cure for HIV; the Company’s expectations regarding its financial
performance, including revenues, expenses, gross margins,
profitability, liquidity, capital expenditures and income taxes;
and, the Company’s estimates regarding its capital requirements. We
refer current and potential investors to the “Risk Factors” section
of our Annual Information Form dated February 23, 2022 available on
SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to
our report on Form 40-F dated February 24, 2022 under
Theratechnologies’ public filings. The reader is cautioned to
consider these and other risks and uncertainties carefully and not
to put undue reliance on forward-looking statements.
Forward-looking statements reflect current expectations regarding
future events and speak only as of the date of this press release
and represent our expectations as of that date. We undertake no
obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise, except as may be required by
applicable law
Investor and Media Contact:Elif
McDonaldSenior Director, Investor
Relationsir@theratech.com438-315-8563
Theratechnologies (TSX:TH)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theratechnologies (TSX:TH)
Historical Stock Chart
Von Apr 2023 bis Apr 2024